AI drug discovery validates platform speed
The bull case presented by Iambic's CEO was that its AI-driven drug discovery platform can get candidates to clinic in a third of the industry average time, validating the approach.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.